血液肿瘤药物市场按治疗类别、适应症、给药途径、通路和最终用户划分－2025-2032年全球预测

预计到 2032 年，血液癌症治疗市场将成长至 1,029.5 亿美元，复合年增长率为 10.59%。

本文从战略角度概述了科学进步、不断变化的法规环境以及商业性需求如何影响血液肿瘤治疗领域的治疗路径和相关人员的优先事项。

血液肿瘤治疗领域正经历快速的科学进步和策略调整，这正在重塑治疗路径、医疗服务模式和商业性策略。标靶治疗、免疫疗法和移植技术的进步，以及分子诊断和数位化工具的改进，正在推动更个人化的治疗流程的发展。同时，支付方和医疗服务提供者也不断改进其价值评估和报销方式，日益重视真实世界数据和以病人为中心的治疗结果在商业规划中的作用。

临床创新、诊断进步和商业性前景正在汇聚，重新定义血液肿瘤学的治疗方法和治疗模式。

血液肿瘤的治疗模式正沿着多个互补的方向转变，治疗模式也随之改变。在临床上，细胞疗法和双特异性疗法的成熟拓展了治疗选择，使其超越了传统的细胞毒性疗法，使既往难治性患者群体也能获得深度且持久的疗效。同时，精准靶向的小分子药物和抗体药物复合体（ADC）透过提高治疗效果指标和提供口服维持治疗策略，正在改变疾病的长期管理。

2025年美国关税调整对血液肿瘤药物供应链韧性筹资策略与商业规划的影响

美国近期调整的关税政策将于2025年生效，这增加了製造商、合约合作伙伴和医疗保健采购商跨境采购零件、试剂和成品生技药品的复杂性。某些原材料和特殊零件关税的提高，以及海关摩擦的加剧，增加了部分供应链的准入成本，促使製造商重新评估其筹资策略，并加快对地域分布广泛的替代供应商进行资格认证。

针对治疗领域、适应症、给药途径、分销管道和最终用户环境的详细细分观点指南战术性优先排序。

细分市场分析揭示了不同治疗领域、适应症、给药途径、通路和终端用户之间的细微差别，这些差异对于优先分配研发和商业资源至关重要。按治疗领域划分，我们的目标领域包括化疗、免疫疗法、干细胞移植和分子标靶治疗，每个领域都有其独特的临床价值提案和营运需求。虽然化疗仍然是某些适应症的基石疗法，但它正面临着来自免疫疗法和分子标靶药物日益激烈的竞争，这些疗法在某些患者群体中具有更好的耐受性和持久缓解效果。我们以适应症为基础的产品组合涵盖白血病、淋巴瘤、多发性骨髓瘤和骨髓发育不良症候群。白血病进一步分为急性淋巴性白血病、急性骨髓性白血病、慢性淋巴性白血病和慢性骨髓性白血病。淋巴瘤进一步分为何杰金氏淋巴瘤和非何杰金氏淋巴瘤。同时，多发性骨髓瘤的治疗方案被分为第一线、第二线、三线及后续治疗。这些更细緻的适应症将决定临床试验设计、监管终点和治疗顺序策略，而特定的亚型则为标靶治疗和细胞治疗介入提供了更明确的途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩大下一代CAR-T细胞疗法在难治性血液肿瘤患者的应用，以对抗復发
• 增加对双特异性抗体平台的投资，用于白血病中的标靶双抗原结合。
• 透过将微小残留病灶监测与数位生物标记结合，实现个人化治疗方法
• 口服BTK抑制剂的进步提高了患者的依从性，并减少了对输液中心的依赖。
• 利Rituximab生物相似药的出现将促进成本竞争，并扩大治疗的可近性。
• 表观遗传调变器标靶组蛋白甲基转移酵素治疗多发性骨髓瘤的临床评价
• 新型连接子在提高淋巴瘤选择性方面的抗体药物复合体开发平臺取得进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按治疗类别分類的血液癌症药物市场

• 化疗
• 免疫疗法
• 干细胞移植
• 标靶治疗

第九章 血液肿瘤药物市场（依适应症划分）

• 白血病
  • 急性淋巴性白血病
  • 急性骨髓性白血病
  • 慢性淋巴性白血病
  • 慢性骨髓性白血病
• 淋巴瘤
  • 何杰金氏淋巴瘤
  • 非何杰金氏淋巴瘤
• 多发性骨髓瘤
  • 一线治疗
  • 二级治疗
  • 第三线及以后
• 骨髓发育不良症候群

第十章 血液肿瘤药物市场（依给药途径划分）

• 静脉注射
• 口服
• 皮下注射

第十一章 血液肿瘤药物市场（依通路划分）

• 医院药房
• 网路药房
• 零售药房

第十二章 血液肿瘤药物市场（依最终用户划分）

• 诊所
• 居家医疗
• 医院

第十三章：血液肿瘤药物市场区域概览

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 血液肿瘤药物市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国血液肿瘤药物市场概况

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis AG
  • AstraZeneca plc
  • Gilead Sciences, Inc.
  • Sanofi SA

The Blood Cancer Drugs Market is projected to grow by USD 102.95 billion at a CAGR of 10.59% by 2032.

A strategic overview of scientific momentum regulatory shifts and commercial imperatives shaping treatment pathways and stakeholder priorities across blood cancer therapeutics

The blood cancer therapeutics landscape is undergoing a period of rapid scientific progress and strategic recalibration that is reshaping treatment pathways, care delivery models, and commercial approaches. Advances in targeted agents, immune-based therapies, and transplant technologies are intersecting with improved molecular diagnostics and digital tools to create more personalized treatment algorithms. Concurrently, payers and providers are evolving their approaches to value assessment and reimbursement, elevating the importance of real-world evidence and patient-centered outcomes in commercial planning.

This introduction sets the stage for an evidence-driven executive summary that synthesizes the most consequential developments shaping drug development, regulatory interactions, manufacturing, and access for hematologic malignancies. The intent is to provide a clear, business-focused orientation that equips decision-makers with the contextual understanding necessary to assess investment priorities, alliance opportunities, and operational adjustments. By framing scientific momentum alongside commercial and policy forces, stakeholders can better align R&D, supply chain resilience, and market access strategies to deliver durable patient benefit while managing financial and regulatory risk.

Converging clinical innovations diagnostic advances and commercial expectations that are collectively redefining therapeutic approaches and access models in hematologic oncology

The landscape for blood cancer therapeutics is shifting along multiple, mutually reinforcing axes that together are transforming care paradigms. Clinically, the maturation of cellular therapies and bispecific modalities is expanding treatment options beyond traditional cytotoxic approaches, enabling deep and durable responses in previously refractory populations. At the same time, precision-targeted small molecules and antibody-drug conjugates are refining therapeutic indices and offering oral maintenance strategies that change long-term disease management.

On the diagnostic and digital front, broader adoption of next-generation sequencing and minimal residual disease assays is enabling earlier intervention and more adaptive treatment sequencing. These diagnostic capabilities are creating opportunities for companion diagnostics and for trial designs that accelerate regulatory interactions. Commercially, payers are increasingly demanding robust real-world evidence and outcome-based contracting, which is redirecting investments toward post-approval evidence generation and patient support mechanisms. Manufacturing advances in cell therapy and biologics scale-up, alongside advances in cold-chain logistics and contract manufacturing capacity, are reducing some barriers to broader adoption while introducing new operational complexities. Taken together, these shifts are producing a more nuanced, multidisciplinary ecosystem where clinical efficacy, manufacturability, evidence generation, and commercial access must be considered in parallel to succeed.

How recent United States tariff adjustments have reshaped supply chain resilience sourcing strategies and commercial planning for blood cancer therapeutics in 2025

Recent tariff adjustments enacted in the United States during 2025 have introduced a layer of complexity for manufacturers, contract partners, and healthcare purchasers that source components, reagents, and finished biologics across borders. Increased duties and customs friction on certain raw materials and specialized components have elevated the cost of entry for some supply chains, prompting manufacturers to revisit sourcing strategies and to accelerate qualification of alternative suppliers in geographically diversified locations.

Beyond direct input costs, tariffs have also influenced logistics and inventory practices. Firms have responded by increasing buffer inventories, qualifying additional contract manufacturing organizations, and accelerating onshoring initiatives for critical processes where feasible. These responses mitigate immediate supply risk but introduce working capital implications and may shift lead times for product availability. Payers and providers are observing these operational adjustments and are increasingly attentive to unit cost trends and procurement predictability, which influences negotiation dynamics and formulary decisions.

In response, industry actors are prioritizing tariff impact assessments within commercial planning, embedding sensitivity analyses into pricing and contracting scenarios, and enhancing traceability across multi-tier supply networks. Policy engagement and coalition-building with trade and industry associations are also being used to communicate clinical and supply implications to policymakers. While tariffs have not altered the fundamental clinical value propositions of novel therapies, they have amplified the importance of supply chain agility, transparent cost drivers, and coordinated payer-provider-manufacturer dialogue to preserve patient access and treatment continuity.

Deeply granular segmentation perspectives across therapeutic classes indications routes of administration distribution channels and end user settings that guide tactical prioritization

Segmentation insights reveal nuanced implications across therapeutic class, indication, route of administration, distribution channel, and end user that are essential for prioritizing development and commercial resources. Based on therapeutic class, the landscape spans chemotherapy, immunotherapy, stem cell transplant, and targeted therapy, each with distinct clinical value propositions and operational demands; chemotherapy remains a cornerstone for some indications but faces increasing competition from immunotherapies and targeted agents that offer improved tolerability or durable remission in select populations. Based on indication, the portfolio covers leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, with leukemia further defined into acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia, and lymphoma split into Hodgkin lymphoma and non-Hodgkin lymphoma, while multiple myeloma is examined across first line, second line, and third line and later settings; these granulated indications dictate trial design, regulatory endpoints, and sequencing strategies, with certain subtypes presenting clearer paths for targeted or cell-based interventions.

Based on route of administration, therapies delivered intravenously, orally, or subcutaneously present distinct adherence, monitoring, and outpatient care considerations that influence patient support programs and reimbursement mechanisms. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies create differentiated logistics, dispensing, and prior authorization workflows that affect time-to-treatment and patient experience. Based on end user, clinics, home care, and hospitals represent divergent care settings where administration complexity, supportive-care needs, and reimbursement rules vary; home care expansion for oral and subcutaneous agents has meaningful implications for patient convenience and adherence programs, whereas complex cellular therapies necessitate coordination across specialized centers and transplant units. Integrating these segmentation lenses enables more precise commercial targeting, optimized trial recruitment strategies, and pragmatic planning for manufacturing scale and distribution complexity.

Tailored regional strategies and regulatory pathways across the Americas Europe Middle East Africa and Asia Pacific that determine access commercialization and clinical trial approaches

Regional dynamics materially influence clinical development pathways, regulatory approaches, and commercialization strategies, and three macro-regions warrant focused consideration. In the Americas, a combination of advanced clinical trial infrastructure, established payer systems, and strong venture and biopharma investment continues to drive rapid adoption of innovative therapies; reimbursement negotiations and health technology assessments are central to commercialization timelines, and U.S. regulatory mechanisms and specialty pharmacy networks set influential precedents for pricing and access agreements. Europe, Middle East & Africa presents a heterogeneous environment where centralized regulatory pathways coexist with diverse national reimbursement frameworks; access is often mediated by health technology appraisal processes and risk-sharing agreements, and regional supply chain hubs and clinical research networks offer opportunities for pan-regional trials and manufacturing collaboration. Asia-Pacific is characterized by a rapidly expanding patient population, growing domestic biopharma capabilities, and increasing regulatory harmonization in some markets, which together create significant opportunities for enrollment in clinical programs and for regional manufacturing scale-up, while payer constraints and price sensitivity in select countries require tailored access strategies and tiered pricing approaches.

Understanding these regional contours supports differentiated go-to-market plans, regulatory sequencing, and partnership models that account for country-level manufacturing capacity, reimbursement complexity, and patient access pathways. Cross-regional learning-such as leveraging real-world evidence generated in one jurisdiction to support value arguments elsewhere-can accelerate access when deployed thoughtfully and in alignment with local regulatory and payer expectations.

Corporate strategies and operational plays that combine scientific leadership partnerships and manufacturing agility to translate therapeutic innovation into clinical adoption

Company-level dynamics in the blood cancer therapeutics domain are increasingly shaped by strategic portfolio diversification, collaborative development models, and investments in specialized manufacturing and evidence generation. Leading developers are blending late-stage clinical programs in cellular and targeted therapies with earlier-stage assets that address unmet needs in refractory or molecularly defined subpopulations. Partnerships between biologics developers, diagnostics companies, and contract manufacturers are becoming standard to accelerate time to clinic and to ensure alignment between companion diagnostics and therapeutic launch plans.

Commercial strategies emphasize differentiated patient support offerings, including enhanced adherence programs for orally administered agents and integrated care coordination for cell therapies requiring multidisciplinary centers. Firms are also prioritizing post-approval evidence programs to address payer demands for real-world effectiveness and health economic outcomes. On the operational side, investments in flexible manufacturing capacity and multi-source supply chains are being used to hedge against geopolitical and tariff-driven risks. Corporate development activity reflects a preference for bolt-on acquisitions that provide either platform technologies, niche pipeline assets, or capacity for biologics and cell therapy production. Overall, successful companies combine scientific leadership with disciplined execution across regulatory interactions, payer engagement, and supply chain orchestration to translate clinical promise into sustainable patient access.

Practical strategic imperatives for leaders to align development evidence supply resilience and patient-centered access to accelerate adoption and manage policy risk

Industry leaders should adopt a set of prioritized, actionable measures to navigate the evolving clinical, commercial, and policy landscape for blood cancer therapeutics. First, align early development with evidence pathways that address both regulatory approval and payer value frameworks, embedding real-world endpoints and health economic measures into pivotal and post-approval programs. Second, diversify sourcing and invest in flexible manufacturing capabilities while accelerating qualification of alternate suppliers and regional contract manufacturers to reduce tariff and logistics exposure. Third, design patient-centric access models that reflect route-of-administration differences and support home-care delivery where clinically appropriate, enabling broader uptake while managing total cost of care implications.

Fourth, pursue strategic collaborations that integrate diagnostics, therapeutics, and data platforms to enable precise patient selection and to strengthen value propositions. Fifth, engage proactively with payers and policymakers through transparent evidence-sharing and pilot agreements that demonstrate impact on clinically meaningful outcomes and system-level efficiencies. Sixth, prioritize commercial capabilities that support complex product launches, including specialty pharmacy partnerships, digital adherence tools, and robust hub services for multi-step therapies. Finally, institutionalize scenario planning and sensitivity analyses for macroeconomic and trade policy variables to ensure rapid adaptation when external conditions shift. Collectively, these recommendations create a resilient framework for translating innovation into sustained patient access and commercial viability.

A rigorous mixed methods approach combining stakeholder interviews regulatory data and supply chain analysis to produce evidence triangulated insights and documented assumptions

The research methodology underpinning this executive summary integrates multi-source evidence and stakeholder input to ensure robust, actionable conclusions. Primary evidence collection included structured interviews with clinical investigators, commercial leaders, manufacturing specialists, and payer representatives to capture contemporary practice patterns, operational constraints, and reimbursement considerations. Secondary analysis drew on regulatory approvals, clinical trial registries, published peer-reviewed literature, and public health guidance to map therapeutic modalities, trial endpoints, and safety profiles in a reproducible manner.

Supply chain and tariff impact assessments used import/export data, contract manufacturing mappings, and logistics performance indicators to evaluate sourcing risk and lead-time vulnerabilities. The approach emphasized triangulation-cross-validating findings across primary interviews, regulatory documents, and operational datasets-to reduce bias and enhance confidence in conclusions. Analytical limitations were addressed by transparently documenting assumptions, distinguishing empirical observations from expert opinion, and noting areas where emerging data could shift interpretations. Quality assurance processes included peer review by subject matter experts and consistency checks across segmentation and regional analyses to ensure coherence and practical relevance for decision-makers.

Synthesis and forward-looking perspective emphasizing integrated operational evidence and access strategies to convert innovation into timely patient benefit

In conclusion, the blood cancer therapeutics field is at an inflection point where clinical innovation, diagnostic precision, and evolving payer expectations intersect to create both opportunity and complexity. The success of novel agents will depend as much on demonstrable patient benefit as on the ability to deliver therapies reliably, to generate meaningful real-world evidence, and to design reimbursement approaches that reflect long-term value. Supply chain pressures and trade policy dynamics have highlighted the importance of operational resilience as an integral component of commercial readiness.

Decision-makers should therefore adopt integrated strategies that align scientific prioritization with manufacturability, payer engagement, and patient-centric delivery models. Those who proactively address evidence requirements, diversify supply options, and build flexible commercial capabilities will be best positioned to convert scientific advances into durable improvements in patient outcomes while maintaining financial and operational sustainability. The path forward requires collaboration across developers, clinicians, payers, and policymakers to ensure that therapeutic innovation translates into equitable and timely access for patients living with hematologic malignancies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of next-generation CAR T-cell therapies addressing relapse in refractory blood cancer patients
• 5.2. Rising investment in bispecific antibody platforms for targeted dual antigen engagement in leukemias
• 5.3. Integration of minimal residual disease monitoring with digital biomarkers to personalize treatment regimens
• 5.4. Advancements in oral BTK inhibitors improving patient adherence and reducing infusion center dependency
• 5.5. Emergence of biosimilar rituximab alternatives driving cost competition and wider therapy access
• 5.6. Clinical evaluation of epigenetic modulators targeting histone methyltransferases in multiple myeloma
• 5.7. Pipeline progression of antibody-drug conjugates with novel linkers for enhanced selectivity in lymphoma

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Cancer Drugs Market, by Therapeutic Class

• 8.1. Chemotherapy
• 8.2. Immunotherapy
• 8.3. Stem Cell Transplant
• 8.4. Targeted Therapy

9. Blood Cancer Drugs Market, by Indication

• 9.1. Leukemia
  • 9.1.1. Acute Lymphoblastic Leukemia
  • 9.1.2. Acute Myeloid Leukemia
  • 9.1.3. Chronic Lymphocytic Leukemia
  • 9.1.4. Chronic Myeloid Leukemia
• 9.2. Lymphoma
  • 9.2.1. Hodgkin Lymphoma
  • 9.2.2. Non-Hodgkin Lymphoma
• 9.3. Multiple Myeloma
  • 9.3.1. First Line
  • 9.3.2. Second Line
  • 9.3.3. Third Line And Later
• 9.4. Myelodysplastic Syndromes

10. Blood Cancer Drugs Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Subcutaneous

11. Blood Cancer Drugs Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Blood Cancer Drugs Market, by End User

• 12.1. Clinics
• 12.2. Home Care
• 12.3. Hospitals

13. Blood Cancer Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Blood Cancer Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Blood Cancer Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Bristol-Myers Squibb Company
  • 16.3.2. AbbVie Inc.
  • 16.3.3. Roche Holding AG
  • 16.3.4. Johnson & Johnson
  • 16.3.5. Takeda Pharmaceutical Company Limited
  • 16.3.6. Amgen Inc.
  • 16.3.7. Novartis AG
  • 16.3.8. AstraZeneca plc
  • 16.3.9. Gilead Sciences, Inc.
  • 16.3.10. Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 180. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 197. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 200. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 215. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 218. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 219. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 220. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 269. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 272. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 273. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 274. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 276. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 278. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 280. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 287. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 290. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 291. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 292. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 293. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 294. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 295. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 296. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 297. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 298. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 299. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 300. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 301. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 302. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 303. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 308. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 309. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 310. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 311. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 312. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 313. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 314. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 315. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
• TABLE 316. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
• TABLE 317. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 318. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 319. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 320. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 321. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 322. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 323. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 324. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 325. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 326. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 327. ASEAN BLOOD CA